Company news

ALX Oncology Holdings Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 7, 2024

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

August 5, 2024

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

July 30, 2024

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

June 1, 2024

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 28, 2024

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

ALX Oncology Appoints Allison Dillon as Chief Business Officer

May 6, 2024

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

April 29, 2024

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

April 23, 2024

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

April 8, 2024

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 6, 2024

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

March 4, 2024

ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023

ALX Oncology Announces November Investor Conference Participation

October 31, 2023

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 9, 2023

ALX Oncology Announces Pricing of Public Offering

October 4, 2023

ALX Oncology Announces Proposed Public Offering

October 3, 2023

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

October 2, 2023

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

October 1, 2023

ALX Oncology Realigns Executive Leadership Team

September 5, 2023

ALX Oncology Announces September Investor Conference Participation

August 30, 2023

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

August 9, 2023

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

June 25, 2023

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 10, 2023

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

May 8, 2023

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

April 24, 2023

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

March 12, 2023

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

March 8, 2023

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

February 15, 2023

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

January 4, 2023

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

December 11, 2022

ALX Oncology Appoints Scott Garland to its Board of Directors

November 28, 2022

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

November 7, 2022

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

November 2, 2022

ALX Oncology Announces Upcoming Investor Conference Participation

November 1, 2022

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

October 30, 2022

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

October 4, 2022

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

September 20, 2022

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

August 15, 2022

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

August 14, 2022

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

August 10, 2022

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

August 7, 2022

ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma

July 31, 2022

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia

June 28, 2022

ALX Oncology Announces Evorpacept Clinical Program Updates

June 2, 2022

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

May 8, 2022

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

April 11, 2022

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

March 1, 2022

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 8 decks. Every deck is listed under its year.